🇺🇸United States·March 26, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 26, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity management through debt amendments/extensions (e.g., WYTEC, Profusa, Diameter Credit), equity raises (Health In Tech $7M PIPE, SmartKem $2.6M), and new credit facilities (Stone Point $250M revolver, Masco $1B), signaling ongoing distress but proactive refinancing amid high interest rates. Outright distress peaks with Broad Street Realty's Chapter 7 bankruptcy liquidation and delistings for FiscalNote (NYSE to OTC) and Cambium Networks (Nasdaq suspension March 27, 2026), while reverse splits (Advantage Solutions 1:25) highlight share price pressures. Period-over-period trends show mixed resilience: Synchrony Card portfolio payment rates up to 24.29% monthly avg in 2026 vs 23.47% in 2025 with 95.1% current accounts; MeiraGTx service revenue -81% YoY but net loss improved 23% to $114.2M. Positive M&A catalysts like OLAPLEX $1.4B sale (55% premium), SSR Mining $1.5B asset sale (Q3 2026 close), and Equitable-Corebridge $22B merger (10% EPS accretion by 2028) offer deleveraging paths. Capital allocation leans toward debt reduction/repayment (Wolfspeed $475.9M refinancing saves $62M annual interest), with no major dividend cuts but dilution risks from warrants/equity. Overall, 7/31 filings indicate severe distress (bankruptcy/delistings), but 15+ show financing successes, implying selective opportunities in refinancings vs high bankruptcy risk in microcaps.

31 high priority31 total filings

🇺🇸United States·March 26, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 26, 2026

Broad Street Realty, Inc., the sole filing in this USA Bankruptcy & Insolvency stream, voluntarily petitioned for Chapter 7 bankruptcy on March 20, 2026, in the U.S. Bankruptcy Court for the District of Delaware (Case No. 26-10398-KBO), signaling total liquidation and cessation as a going concern. George L. Miller was appointed Chapter 7 Trustee to oversee asset liquidation and creditor payments, immediately stripping the Board of Directors and executives of all authority. CFO Alexander Topchy resigned effective the same date, underscoring acute management distress amid the collapse. No period-over-period financial trends or forward-looking guidance are viable post-filing, as operations end; sentiment is uniformly negative with 10/10 materiality. This development implies imminent equity wipeout, with portfolio implications for real estate exposure: delisting likely, zero recovery for shareholders. Overarching theme: isolated but extreme insolvency event highlights vulnerability in commercial realty amid presumed prior deteriorating metrics like rising debt or occupancy declines.

1 high priority1 total filings

🇺🇸United States·March 25, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 25, 2026

The 35 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in listing compliance risks, with at least 5 companies (Longeveron, SOBR Safe, Mainz Biomed, SelectQuote, CIMG) facing Nasdaq/NYSE delisting threats due to sub-$1.00 bid prices, often after prior reverse splits or amid weak stock performance. Debt restructurings dominate, with 12+ amendments/extensions to credit agreements (e.g., Cipher Mining, Synergy CHC, Mobile Infrastructure's third amendment) signaling liquidity strains and covenant relief needs, though some like Albemarle extend maturities positively. Equity capital raises via low-price offerings (Twin Vee at $0.384/share, Next Technology $157M) and terminations (Volato) highlight dilution risks for microcaps, contrasting positive M&A like Merck's $6.7B Terns buy and Sandisk's $1B Nanya investment. Period trends show outliers like CIMG's Q1 FY2026 revenue exploding +69000% YoY to $15.8M from $22k, but broader distress with operational restructurings (EnerSys $37M charge for plant closure, $20M FY2028 savings). Capital allocation leans toward debt extensions over dividends/buybacks, with no insider buying/selling noted across filings. Portfolio implication: Heightened short opportunities in sub-$1 names, monitor Q2 2026 catalysts like Terns close and compliance deadlines.

35 high priority35 total filings

🇺🇸United States·March 24, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 24, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream spanning 40 filings (28 new), overarching themes reveal acute liquidity pressures with 12 companies securing covenant waivers/amendments (e.g., FTC Solar waiving purchase order breach, Southland assigning $110M loans), 4 facing Nasdaq delisting risks (BNB PLUS, SurgePays, Hub Group delay, implied others), and one outright restructuring (Cannabist CCAA/Chapter 15 with asset sales). No uniform period-over-period declines in revenue/EBITDA, but distress signals include covenant breaches (FTC Solar Q4 2025), delayed 10-Ks (Hub Group restating Q1-Q3 2025), and high-cost financings (NightFood 15% OID note). Positive offsets: 8 new/expanded facilities (Aardvark $150M ATM, Portland GE $350M term loan, Innodata $50M credit), asset sales for debt paydown (Krispy Kreme $160M total, CVD $16.9M), and buybacks (Robinhood $1.5B). Portfolio trends show small-cap biotechs/construction with 70% mixed/negative sentiment vs. energy/finance at 40%; margin trends N/A but EBITDA covenants tightened (FTC Solar $10M min 2026). Critical implications: Elevated bankruptcy risk in cannabis (Cannabist) and solar (FTC Solar stringent ramps); turnaround alpha in refranchising (Krispy) and refinancings (Moog extending 7 years). Actionable now: Avoid delisting candidates, monitor Q2 2026 catalysts.

40 high priority40 total filings

🇺🇸United States·March 24, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 24, 2026

The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) filing from Cannabist Co Holdings Inc., signaling acute distress in the cannabis sector with initiation of CCAA proceedings in Canada and planned Chapter 15 in the US to enable asset sales and orderly wind-down. Operations have ceased in New York and are ceasing in Pennsylvania, amid persistent operational challenges, with trading halt and delisting review imminent. Key asset divestitures include a closed $130M Virginia sale, pending $16.5M Delaware cash deal (Q2 2026 close), $47M Ohio sale ($34.5M cash + $12.5M note, Q3 2026 close), and a non-binding MOU for remaining assets in six states. Supporting noteholders (>60% of 9.25% Senior Secured Notes due 2028 and 9.0% Convertible Notes due 2028) endorse transactions, providing some creditor backing but underscoring equity wipeout risk. No period-over-period financial trends available, but operational contractions highlight deteriorating performance. Market implications include zero equity value potential, distressed asset opportunities, and broader cannabis sector contagion risks.

1 high priority1 total filings

🇺🇸United States·March 23, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 23, 2026

Across 46 filings in the USA Corporate Distress & Bankruptcy stream (32 new), the dominant theme is aggressive liquidity bolstering via 18+ new/expanded credit facilities, 12 equity/debt raises, and 8 refinancings extending maturities (avg ~3yrs) and cutting rates (e.g., California Resources 8.25% to 7%), signaling stabilization rather than deepening distress. Period-over-period highlights include Sutro Biopharma's FY2025 revenue +65% YoY to $102.5M, R&D -34% to $166.4M, net loss improved -16% to $191.1M; RenovoRx $900k rev in 9M2025 from commercialization. Insider conviction strong in RenovoRx (mgmt/board participation), Empery Digital ($200M buybacks at $5.92 avg). Critical developments: Volato NYSE delisting risk (equity < $2M/4M), MSP Recovery liquidity crunch ($75k advance + CRO). Portfolio trends: Positive sentiment 60% (28/46), financing materiality avg 8/10; bearish outliers in microcaps. Implications: Short-term survival plays dominant, alpha in refi beneficiaries and biotech catalysts, monitor delistings for shorts.

46 high priority46 total filings

🇺🇸United States·March 20, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 20, 2026

Across 41 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is acute small-cap distress with 13 companies (e.g., GoHealth, Quince Therapeutics, MaxCyte, NextNRG, Ernexa, Tivic, Heritage/IPST, Faraday Future, Tela Bio, Alzamend Neuro) receiving Nasdaq deficiency notices for bid price < $1.00 over 30 days, MVLS/equity shortfalls, or audit committee issues, risking delisting by Sep 2026; Zynex confirmed Ch11 reorganization with equity cancellation (no recovery for 30.8M shares). Period-over-period trends show revenue declines (Beasley Broadcast -8.7% CAGR FY23-25 to $206M, audio -11.8%), but some improvements like Spruce Biosciences net loss -26% YoY to $39M FY25 and Embecta/Prestige accretive M&A. Forward-looking catalysts cluster in H1-Q3 2026: merger closings (KORE $9.25/share, Dillard's), compliance deadlines (180 days to Sep), Zynex emergence by Mar31; financings (TG Therapeutics $750M term loan, Fortive $2B revolver) signal liquidity support amid distress. Capital allocation leans defensive (debt paydowns, no dividends/buybacks noted except Fair Isaac $1B notes for repurchases), with insider reliance (Perfect Moment $5M chairman loans extended). Portfolio-level: Biotech/healthcare outliers in delisting risks (8/13), while consumer/energy M&A bucks trend; implications include short opportunities in non-compliant microcaps, long setups in turnaround financings/M&A.

41 high priority41 total filings

🇺🇸United States·March 20, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 20, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical development: Zynex Inc.'s Chapter 11 reorganization plan confirmation on March 19, 2026, marking the culmination of proceedings initiated December 15, 2025, with emergence expected by March 31, 2026. All 30,781,021 existing common shares are cancelled with zero recovery for equity holders, transferring 100% ownership (approximately 1,000 new shares) to the Plan Sponsor and providing DIP Lenders $10M in takeback debt. No period-over-period financial trends are detailed in the filing, but the Nasdaq delisting (effective February 2, 2026) and OTC trading as ZYXIQ underscore speculative risks and total equity wipeout. Market implications include complete shareholder value destruction, heightened volatility in OTC trading, and a bearish sentiment (rated negative, materiality 10/10). Portfolio-level patterns are limited to this filing, but it exemplifies ongoing corporate insolvency pressures in the medical device sector, with no insider activity, capital allocation, or forward guidance beyond plan effectiveness noted.

1 high priority1 total filings

🇺🇸United States·March 19, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 19, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (34 new), dominant themes include aggressive liquidity raises via high-interest debt ($225M American Vanguard term loan, $3.75M SmartKem notes), equity offerings (SAB Biotherapeutics public offer, Twin Vee $1.7M ATM), and covenant amendments/extensions signaling covenant breaches (Cannabist forbearance to Mar25 2026, VINCE Holding receivables tweaks). Nasdaq/NYSE delisting notices hit AVAX ONE, Skye Bioscience, Getty Images for sub-$1 bids over 30 days, amplifying small-cap distress. No broad YoY revenue declines disclosed, but debt reductions (DevvStream -$5.9M net) and refinancings (Wolfspeed $475.9M lower-cost notes) provide relief outliers; forward-looking catalysts cluster in Q2/Q3 2026 closings (Mount Logan acquisition, Collegium AZSTARYS deal). Portfolio trends: 12+ equity offerings risking dilution (avg ~$50M targeted), 8+ credit amendments (e.g., AES change-of-control for merger), 1 RSA (DISH DBS potential Ch11); mixed sentiment (20 positive, 15 neutral, 10 negative). Implications: elevated bankruptcy risk in biotechs/microcaps, watch Mar25 Cannabist deadline and Nasdaq hearings for forced reverse splits/buyouts.

50 high priority50 total filings

🇺🇸United States·March 18, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 18, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive liquidity pursuits through debt facilities, equity issuances, note extensions, and credit amendments, with 18 companies (58%) announcing new/expanded financing amid potential distress signals like Nasdaq delisting notices in 2 cases and dilutive convertible notes in 5. Period-over-period data is sparse but highlights outliers: Ovid Therapeutics revenue surged 1117% YoY to $7.3M with opex down 20% to $49.7M and net loss halved to $17.4M, contrasting minimal quantitative trends elsewhere. Positive catalysts include M&A (e.g., Independent Bank's $70.2M accretive deal, ConnectM's defense acquisition) and buybacks (ExlService's $125M ASR), while risks cluster around equity dilution, reverse splits, and compliance deadlines into Q3-Q4 2026. Portfolio-level patterns show capital allocation skewed to debt preservation (e.g., Hilton, Socket Mobile extensions) over returns, with no insider buying/selling clusters but related-party deals in 4 filings signaling governance watchpoints. Forward-looking data builds a catalyst calendar heavy on approvals, closings, and trial readouts, implying short-term volatility in microcaps. Overall, distress signals are mixed with turnaround financing opportunities, but Nasdaq risks and high-interest notes flag 7 high-risk names warranting avoidance.

31 high priority31 total filings

🇺🇸United States·March 17, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 17, 2026

Across 42 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity maneuvers via high-cost convertible notes, equity offerings, and debt restructurings (e.g., 10+ issuances of notes/preferred with 15-22% effective rates), Nasdaq compliance failures (4 cases with delisting/reverse split risks), and covenant amendments signaling near-term stress, amid limited explicit YoY/QoQ data but clear patterns of debt settlements reducing burdens (e.g., Integrated Rail settled $705k, i-80 Gold retired $165M). Positive offsets feature major contracts (Duos $176M over 36 months), grants (Clene $8M), and M&A (Public Storage acquiring NSA), with sentiments skewing positive/neutral in 70% of cases despite distress focus. Critical developments like Urgent.ly's imminent delisting and New Fortress Energy's RSA (diluting shareholders to 35%) heighten bankruptcy risks, while refinancings (Indivior $500M at 0.625%, Beazer +43.8% facility) provide relief. Portfolio-level: Small-cap biotechs/tech show repeated dilution/equity raises (12 cases), airlines/construction deferrals indicate capex cuts, no broad margin compression trends evident but liquidity covenants relaxed in 3 filings. Implications: Heightened short opportunities in non-compliant names, long setups in turnaround financings with catalysts.

42 high priority42 total filings

🇺🇸United States·March 16, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 16, 2026

Across 38 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is proactive debt refinancing and extension, with 18 companies (e.g., Airbnb $2.5B notes to repay 0% convertibles, Waste Connections $600M notes, Duke Energy credit extension to 2031) issuing longer-term debt at higher rates (4.4%-6.75%) to manage short-term maturities, signaling avoidance of immediate liquidity crunches amid elevated interest expenses. Real estate players like Armada Hoffler ($562M asset sale for deleveraging to 5.5x-6.5x net debt/EBITDA) and Ares Commercial (facility extension to Dec 2026) show portfolio simplification, while biotech/health firms (Alto $120M placement, Zevra debt-free post-sale) raised capital for pipelines. Period-over-period trends reveal mixed results: Urgent.ly Q4 revenue +4% YoY/gross margin +400bps to 26% but FY revenue -10% YoY/cash down to $5.3M; TeraWulf FY2025 net loss $661M on $168.5M revenue; Spirit Airlines Chapter 11 projects FY26 revenue +6.1% YoY to $3B but net loss $111M. Distress signals include Lyra Therapeutics delisting (March 17, 2026), Outlook Therapeutics going concern (cash $8.7M insufficient), Greenland Nasdaq deficiency. Forward-looking catalysts cluster mid-2026 (e.g., AHRT closings, WisdomTree acquisition Q2), with no broad insider selling but capital allocation favoring deleveraging over dividends/buybacks. Portfolio-level: Margin expansions in 3/5 reporting firms (avg +200bps QoQ) offset by revenue declines in 4/10 (avg -8% YoY), highlighting sector-specific resilience in refinancing markets.

38 high priority38 total filings

🇺🇸United States·March 13, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 13, 2026

Across 41 8-K filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive financing maneuvers (e.g., credit amendments, ATM offerings, debt issuances totaling billions) to bolster liquidity amid scattered distress signals like Nasdaq/NYSE listing deficiencies in 4 companies and debt-for-equity swaps indicating balance sheet strains. No broad period-over-period declines are quantified, but inferred trends show 6/41 companies executing dilutive equity raises or exchanges (e.g., NextNRG's $1.75M debt-for-3.18M shares), contrasting with positive capital raises like Venture Global's $8.6B CP2 Phase 2 FID. Critical developments feature imminent delistings (Bio Green Med's preferred stock suspension March 23, 2026) and compliance grace periods (Talphera until Sept 7, 2026; Azitra until Apr 1, 2027), signaling heightened bankruptcy risks for microcaps in pharma/biotech. Portfolio-level patterns reveal sector-agnostic distress financing, with energy/oil (Battalion, 1606 Corp) pursuing accretive acquisitions while tech/pharma (Azitra, Talphera) face equity erosion. Overall, 22/41 neutral/positive sentiments mask underlying pressures, urging vigilance on dilution and listing catalysts for short-term trading opportunities.

41 high priority41 total filings

🇺🇸United States·March 12, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 12, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, overarching themes reveal acute liquidity pressures driving 28+ capital raises/debt refinancings (e.g., $30M Longeveron private placement, $673M Dianthus equity), 12 credit amendments/waivers signaling covenant strain (XBP eliminating min availability, NGL ABL cut to $425M), and 5 delisting/reverse split risks (Cryo-Cell NYSE warning, Allurion to OTC, CXApp extension to Sep 2026). Period-over-period data sparse but highlights distress: Universal Electronics FY2025 sales -7% YoY to $368M, Q4 -21% to $87M despite margin expansion to 29.7% and op cash $23.6M; no broad YoY revenue growth, with declines/outliers in sales volumes/cash burn implied across microcaps. Insider activity minimal, but board changes (Turtle Beach activist settlement, Beneficient Hicks appt) suggest governance shifts amid distress. Forward-looking catalysts cluster in Q2-Q4 2026: trial readouts (Longeveron 3Q26), mergers (NIMU Jun30), note redemptions (Chemours 2027 notes). Portfolio implications: broad small/midcap distress via dilutive equity (NIMU 95.5% dilution, ECD 207M shares), higher-cost debt (Chemours 7.875% vs prior 5.75%), but successful raises extend runways (Firefly to 2027 lockups); short high-dilution names, buy post-stabilization refinancings.

50 high priority50 total filings

🇺🇸United States·March 11, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 11, 2026

Across 32 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq minimum bid price non-compliance (GameSquare, VYNE Therapeutics, SmartKem) granting extensions to Sep 2026, signaling persistent stock price weakness and delisting risks; dilutive financings via convertible notes/promissory notes (CERO Therapeutics $937.5k note at $0.05 conversion, SunPower $10M debenture at $2.50/share, Liberty Star $110k note); defensive shareholder rights plans (Starz at 17.5% trigger, Enzon extension); and liquidity support through credit facilities/extensions (Consolidated Edison $3.5B revolver, Advantage Solutions ABL amendment). Positive M&A offsets distress with Cintas/UniFirst $5.5B deal at 8.0x EBITDA (Cintas Q3 rev +8.9% YoY to $2.84B), Sphere 3D/Cathedra bitcoin mining merger (53MW capacity), Aureus/Powerus drone merger ($50M investment). Limited period trends show revenue growth outliers (Cintas +8.9% YoY organic +8.2%), but no widespread margin compression or YoY declines; neutral/mixed sentiment dominates (22/32), with 6 positive. Implications: Heightened short-term volatility from compliance deadlines, dilution risks eroding equity value, but M&A catalysts offer turnaround potential in services/tech.

32 high priority32 total filings

🇺🇸United States·March 10, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 10, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream, key themes include widespread dilutive equity raises (12+ companies, e.g., AN2 $40M at $2.85/share ~20% dilution potential, US Energy $8.2M), debt refinancings/extensions (15+ firms like AECOM $2.95B facilities, Hallador $120M to 2029), and Nasdaq delisting risks/reverse splits (5 cases: SolarMax, OSR Holdings, ClearSign 1:10, Origin 1:30, PMGC 6:1) signaling microcap distress. One outright bankruptcy confirmation (Nine Energy prepackaged plan in 33 days). Period-over-period trends mixed: EBITDA -4% YoY at Walker & Dunlop to $316M amid volume drops; KDP Coffee sales +1% YoY to $4.7B but net income -5% YoY to $700M, OCF +37% YoY to $629M; BlackLine margins +6% over 2 years with 2026 revenue guide 9.1-9.6%. Larger caps show capital access strength (Eaton $8.5B notes, FIS $6.8B), while biotechs/energy services cluster distress signals. Portfolio implications: Distress confined to small caps (low participation warrant exchanges like Guided 22.7%), potential alpha in post-reorg plays but contagion risk from Nasdaq failures.

45 high priority45 total filings

🇺🇸United States·March 10, 2026·daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 10, 2026

The USA Bankruptcy & Insolvency stream features one key filing from Nine Energy Service, Inc., confirming its Amended Joint Prepackaged Chapter 11 Plan of Reorganization on March 4, 2026, just 33 days after petitioning on February 1, 2026, in the U.S. Bankruptcy Court for the Southern District of Texas (Case No. 26-90295). This rapid prepackaged process, backed by an RSA with over 70% of Senior Secured Notes holders and 100% of Prepetition ABL Claims holders, and completed with no unresolved objections, underscores acute debt distress in the energy services sector but demonstrates strong creditor alignment for a swift emergence. No period-over-period financial metrics, forward-looking guidance, insider trading activity, capital allocation details, or operational metrics were disclosed, limiting quantitative trend analysis but amplifying the negative sentiment (rated negative, materiality 10/10). Market implications include likely dilution or cancellation of existing equity, potential trading halts or delistings, and a cleaner balance sheet post-reorg as a portfolio-level signal of ongoing insolvency pressures in cyclical energy subsectors. This isolated event highlights broader themes of creditor-driven restructurings amid commodity volatility, with no cross-filing comparisons available due to n=1.

1 high priority1 total filings

🇺🇸United States·March 09, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 09, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive capital raising via PIPEs ($85M Korro, $30M MGNC commitment), ATMs ($100M enGene), private placements ($15M Battalion, $11M Envirotech), and debt refinancings/securitizations ($1.6B Optimum, $900M Genesis revolver), signaling liquidity crunches or preemptive balance sheet fortification amid potential distress. Sparse period-over-period data reveals cost discipline in biotech (Spruce opex -40% YoY to $36.5M, net loss improved 26% to $39M) and operational upticks (Battalion oil prod +1,200 bpd Jan vs Dec), but tightening credit covenants (ProFrac availability cut to $275M, min liquidity $45M) and Nasdaq warnings (Cypherpunk < $1 bid 30 days) underscore distress risks. Direct bankruptcy activity limited to TPI Composites' Ch11 asset sale ($20M), with forbearance extensions (Cannabist to Mar 17) and collateral pledges (Jaguar $10.8M note) as red flags. M&A/asset sales (Lisata acquisition $5/share + CVR, Alexanders $235M property) provide cash influxes, while buybacks (United Therapeutics $2B, SLM $200M ASR) reflect conviction in non-distressed names. Portfolio-level: 18/50 filings involve equity dilution, 12 credit amendments/refis (mostly neutral-positive), implying sector-wide deleveraging but vulnerability to covenant breaches; opportunities in post-sale rebounds, risks in biotech trial failures.

50 high priority50 total filings

🇺🇸United States·March 06, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 06, 2026

The 51 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in listing compliance failures, with at least 10 companies (Traeger, Presurance Holdings, Offerpad, Jaguar Health, Beyond Meat, Iveda, Nerdy, Borealis Foods, United States Antimony, Spirit Aviation) cited for sub-$1.00 bid prices over 30 days, triggering 180-day cure periods often reliant on reverse stock splits approved in late 2025/early 2026. Debt restructurings and waivers dominate distressed signals (Nortech covenant waivers on Leverage Ratio/EBITDA, Gran Tierra 90% note exchange at higher 9.75% coupon), alongside impairments (Western Alliance $126.4M non-cash charge) and bankruptcy contexts (Spirit ongoing Ch.11 since Aug 2025). Positive counter-trends include sizable financings (Dave $175M conv notes with $70.5M buybacks, Core Scientific $500M loan expandable to $1B, Solid Biosciences $240M placement extending runway to H1 2028) and M&A (Day One $2.5B acquisition at 68% premium). No aggregate YoY/QoQ revenue/margin trends available across filings, but liquidity injections via $20M+ raises (Allarity, Honeywell up to $16B notes) signal aggressive survival tactics amid neutral-to-mixed sentiments (avg materiality 8/10). Portfolio implications: elevated short-term delisting/bankruptcy risks in small-caps, but select turnarounds via premium deals and debt extensions offer alpha for contrarians.

51 high priority51 total filings

🇺🇸United States·March 05, 2026·daily

US Corporate Distress Financial Stress SEC Filings — March 05, 2026

In the USA Corporate Distress & Bankruptcy intelligence stream covering 51 filings from March 5, 2026, distress signals are limited with only two active Chapter 11 cases (Cumulus Media prepackaged plan with 72% support, TPI Composites asset sales amid DIP default), overshadowed by 20+ positive financings/refinancings (e.g., Pulmonx $60M term loan, Sunrise Realty $165M rev fac expansion) and debt tenders (Sirius XM $499M repurchased, Matador $420M). Period-over-period trends show mixed revenue performance: growth in OptimizeRx (+19% FY2025 YoY), Full House (+3.4% Q4 2025 YoY), but declines in GoPro (-19% FY2025 YoY) and implied sector weakness (Cumulus declining broadcast). Reverse stock splits in 5 small caps (Reviva 1:20, Aditxt/Sky Quarry 1:8, Salarius 1:12) flag microcap distress, while capital allocation leans bullish with buybacks (EPAM $300M ASR, OptimizeRx $10M program) and divestitures (Six Flags $331M for debt paydown, Community Health $112M). Forward-looking catalysts cluster in Q2 2026 (deal closings, approvals), suggesting deleveraging and liquidity boosts could stabilize portfolios. Portfolio implication: overweight structured distress resolutions and financing winners, underweight reverse-split microcaps amid Nasdaq deficiencies (Fly-E).

51 high priority51 total filings